Logo

RGEN

Repligen Corporation

RGEN

Repligen Corporation • NASDAQ
$171.02 ▼ -0.09% (-0.16)
Market Cap $9.63 B
52w High $182.52
52w Low $102.97
Dividend Yield 0%
P/E 8551
Volume 388.21K
Outstanding Shares 56.29M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $188.805M ▲ $83.69M ▲ $14.911M ▲ 7.898% ▼ $0.27 ▲ $46.936M ▼
Q2-2025 $182.366M ▲ $77.246M ▼ $14.866M ▲ 8.152% ▲ $0.26 ▲ $48.335M ▲
Q1-2025 $169.172M ▲ $84.179M ▲ $5.83M ▲ 3.446% ▲ $0.1 ▲ $36.381M ▲
Q4-2024 $167.547M ▲ $75.342M ▼ $-33.869M ▼ -20.215% ▼ $-0.6 ▼ $2.11M ▼
Q3-2024 $154.871M $85.32M $-654K -0.422% $0.32 $21.395M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $748.747M ▲ $2.924B ▲ $840.624M ▲ $2.083B ▲
Q2-2025 $708.855M ▲ $2.902B ▲ $839.886M ▼ $2.062B ▲
Q1-2025 $697.229M ▼ $2.852B ▲ $866.66M ▲ $1.985B ▲
Q4-2024 $757.355M ▼ $2.83B ▼ $856.948M ▲ $1.973B ▼
Q3-2024 $783.964M $2.831B $813.958M $2.017B

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $14.911M ▲ $48.099M ▲ $-7.783M ▲ $-239K ▲ $39.892M ▲ $42.713M ▲
Q2-2025 $14.866M ▲ $28.609M ▲ $-7.839M ▲ $-10.131M ▼ $11.626M ▲ $21.004M ▲
Q1-2025 $5.83M ▲ $15.005M ▼ $-74.108M ▼ $-5.03M ▼ $-60.126M ▼ $10.575M ▼
Q4-2024 $-33.869M ▼ $39.176M ▼ $-64.762M ▼ $1.449M ▲ $-26.609M ▼ $32.188M ▼
Q3-2024 $-654K $49.32M $-5.859M $-69.604M $-25.182M $42.182M

Revenue by Products

Product Q4-2024Q1-2025Q2-2025Q3-2025
Product
Product
 $170.00M ▲$170.00M ▲$180.00M ▲$190.00M ▲
Royalty
Royalty
 $0 ▲$0 ▲$0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement Revenue surged during the pandemic period and then stepped down, now running roughly flat at a lower level than the prior peak. Profitability followed the same pattern: margins were very strong a few years ago, then compressed as growth slowed and costs stayed elevated. Recently, the company slipped into a small loss at the net income level even though underlying operating cash generation remains positive. Overall, the income statement shows a business transitioning from a boom phase into a normalization phase, with solid gross profitability but pressure on operating and net margins while it adjusts its cost base to current demand.

Balance Sheet

Balance Sheet The balance sheet looks generally sound. Total assets and shareholder equity have been building steadily over the last few years, showing reinvestment in the business and retained value. Cash on hand is sizable relative to the company’s scale, giving a useful financial safety buffer. Debt has risen but remains moderate compared with equity, suggesting leverage is not excessive. In simple terms, the company appears to have a strong capital base and enough financial flexibility to support ongoing operations and investment, even as earnings fluctuate.

Cash Flow

Cash Flow Cash generation from day‑to‑day operations has been consistently positive, even in the more recent, weaker earnings period. Free cash flow has also stayed positive each year, though at modest levels, reflecting steady but manageable spending on new facilities and equipment. Capital investment ramped up during the high‑growth years and has since eased somewhat, which should help free cash flow in a more normal demand environment. Overall, the cash flow profile shows a business that funds itself internally and can keep investing without relying heavily on borrowing.

Competitive Edge

Competitive Edge Repligen occupies a specialized niche at the heart of biologic drug manufacturing rather than competing in the crowded drug development space. Its technologies—such as advanced filtration systems, pre‑packed chromatography columns, and single‑use solutions—are deeply embedded in customers’ production lines, making them time‑consuming and risky to replace. This creates meaningful switching costs and helps support pricing power. The company’s focus on bioprocessing, rather than a broad product sprawl, has allowed it to become a recognized expert in several high‑value process steps. The main risks are exposure to capital spending cycles in biopharma and competition from larger, diversified life‑science suppliers that also target these workflows.

Innovation and R&D

Innovation and R&D Innovation is a core strength. Repligen consistently develops and acquires technologies that make biologic manufacturing faster, more efficient, and more reliable. Its portfolio includes tools that enable continuous processing, single‑use manufacturing, and rapid, real‑time process analytics—key themes in modern bioprocessing. The company is also pushing into digital and data‑driven solutions, including partnerships to add machine learning and “digital twin” capabilities, and is tailoring its technologies to newer areas like cell and gene therapy and mRNA production. This emphasis on process improvement and next‑generation modalities helps keep its offerings differentiated but also requires ongoing R&D and integration execution.

Summary

Repligen today looks like a high‑quality, niche bioprocessing company navigating a post‑surge reset. Financially, it has moved from a period of extraordinary growth and profitability to a more normal environment with flatter sales and thinner margins, even posting a recent loss at the bottom line. However, the balance sheet and cash flow remain solid, giving it time to adjust costs and absorb volatility. Strategically, its competitive position is underpinned by specialized technologies, entrenched customer relationships, and a strong innovation engine focused on the future of biologic manufacturing. Key uncertainties center on how quickly end‑market demand grows from here, how well the company aligns its cost structure with that reality, and how effectively it continues to differentiate against larger industry players. Overall, the story is one of durable strategic strengths paired with cyclical and execution risks as the business digests its earlier rapid expansion.

NEWS

November 26, 2025 · 7:30 AM UTC

Repligen Corporation to Present at Evercore Healthcare Conference

Read more

October 28, 2025 · 7:30 AM UTC

Repligen Reports Third Quarter 2025 Financial Results and Updates Full Year 2025 Financial Guidance

Read more

October 15, 2025 · 7:30 AM UTC

Repligen to Report Third Quarter 2025 Financial Results

Read more